When Routine Screening Saves a Life – James' Story
Meet James
A 56-year-old accountant
Father of two
He’s active, generally healthy, and the kind of guy who rarely skips a check-up
What brought him to his doctor this time?
Just some mild urinary changes—waking up a bit more often at night to pee and a slightly weaker stream.
​
At first, James thought it was just part of aging. But with a family history of prostate cancer (his father was diagnosed in his late 60s), his doctor decided to run a PSA blood test and perform a digital rectal exam (DRE)—just to be safe.
Test Results That Raised a Flag
11.2 ng/mL (above the normal range)
[5]
Further Tests ruled out lymph node or bone involvement. His cancer was localized (Stage T2b N0 M0), meaning it hadn’t spread beyond the prostate. [4]
James’ tumor was androgen-sensitive, meaning it relied on testosterone signaling to grow. This is common in early-stage prostate cancer and significantly influences treatment decisions. [29]
The Treatment Conversation
After reviewing his case, the urology-oncology team presented James with a few options:
[25] [9] [24]
Write a title here. Click to edit and add your own.
surgical removal of the prostate
James chose surgery, prioritizing long-term cancer control
One Year Later
At his 12-month follow-up, James’ PSA remained undetectable, and there were no signs of recurrence. He experienced minor side effects but is now back to work and living life fully—grateful that early detection led to a favorable outcome.
What Can We Learn from James' Case?
-
Early prostate cancer often has no symptoms.
-
Routine PSA testing and DREs are powerful tools for early detection, especially in high-risk groups.
-
Understanding tumor biology, like androgen sensitivity, helps tailor treatment.
-
Shared decision-making between patients and healthcare teams is key to good outcomes.